News & Events – Page 4 – Sumitovant

Select Company

July 14, 2021Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
July 06, 2021Urovant Sciences Named One of the 2021 Best Places to Work in Orange County
June 01, 2021Myovant Sciences to Present at Upcoming Investor Conferences
May 26, 2021Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
May 26, 2021Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies
May 21, 2021Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
May 20, 2021Altavant Sciences Reports Rodatristat Ethyl PK/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVATE 2 Study
May 12, 2021Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
May 06, 2021Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension
May 03, 2021Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest
« Previous 1 2 3 4 5 6 … 21 Next »